Cancer Pharmacology Core

The DF/HCC Cancer Pharmacology Core provides investigators with the necessary expertise and resources to design and undertake pharmacokinetic (PK) studies in Phase I and II clinical trials, and preclinical investigations. These studies are essential to the development and evaluation of new drugs and combination regimens for cancer treatment. The core’s services facilitate the acquisition of PK data in a timely and cost-effective manner.

Key Services

  • Experimental design and protocol development
  • Identification and implementation of appropriate procedures for sample handling, processing, and storage prior to analysis 
  • Sample storage and tracking
  • Study oversight
  • Development, validation, and application of analytical methods to measure drugs and their metabolites in biological fluids
  • Metabolite identification
  • Comprehensive PK data analysis and interpretation
  • Correlation analyses to assess the influence of pathophysiologic variables on PK parameters and associations between PK parameters and biological effects, such as toxicity, biological correlates, and therapeutic response
  • Assistance in preparing manuscripts and presentations
  • Development of formulations suitable for drug administration for preclinical PK studies

The Core provides a wide range of consultative services pertaining to the above capabilities, and also has the ability to implement and validate previously developed analytical methods as well as the expertise to modify or develop new assays when warranted.

Publication Acknowledgement

If research supported by this core facility results in publication, please acknowledge this support by including the following in your publication(s):
"We thank Dana-Farber/Harvard Cancer Center in Boston, MA, for the use of the Cancer Pharmacology Core, which provided __________ service. Dana-Farber/Harvard Cancer Center is supported in part by an NCI Cancer Center Support Grant # NIH 5 P30 CA06516."